So sánh phương pháp
Xem các phương pháp đã chọn cạnh nhau; những hàng khác biệt được làm nổi bật.
| Thử nghiệm lâm sàng đa trung tâm Giai đoạn III× | Nghiên cứu Giai đoạn IV× | |
|---|---|---|
| Lĩnh vực | Dịch tễ học | Dịch tễ học |
| Họ | Process / pipeline | Process / pipeline |
| Năm ra đời≠ | 1940s–1990s (formalized through ICH harmonization ~1990s) | Formalised 1970s–1990s (ICH E3 guideline 1994) |
| Người khởi xướng≠ | Codified through ICH E9 guideline (1998) and decades of regulatory practice (FDA, EMA) | Regulatory agencies and pharmaceutical industry (ICH, FDA, EMA frameworks) |
| Loại≠ | Confirmatory interventional study design | Post-marketing observational or interventional study |
| Công trình gốc≠ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385 | International Conference on Harmonisation (ICH). (1994). ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. ICH Secretariat. link ↗ |
| Tên gọi khác | Phase III multicenter RCT, confirmatory multicenter trial, Phase 3 multicenter study, pivotal multicenter trial | post-marketing surveillance study, post-approval study, Phase 4 study, PMS study |
| Liên quan≠ | 6 | 5 |
| Tóm tắt≠ | A multicenter Phase III clinical trial is the definitive confirmatory study that tests whether a new intervention produces a clinically meaningful benefit over a comparator in a large, representative patient population enrolled at two or more independent research sites. It is the primary evidence basis for regulatory approval by agencies such as the FDA and EMA, combining the statistical power of large samples with the external validity gained from geographic and demographic diversity across sites. | A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life. |
| ScholarGateBộ dữ liệu ↗ |
|
|